NBIX vs. RPRX: Neurocrine Biosciences vs. Royalty Pharma Stock Comparison

Company Profile

Neurocrine Biosciences (NBIX) and Royalty Pharma (RPRX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NBIX is classified in Biotechnology while RPRX is classified in Pharmaceuticals.

Neurocrine Biosciences (NBIX) has more than two decades of public-market history since May 23, 1996, whereas Royalty Pharma (RPRX) listed on June 16, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Neurocrine Biosciences (NBIX) at 20.42% and Royalty Pharma (RPRX) at 12.09% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Neurocrine Biosciences (NBIX) at 18.98% and Royalty Pharma (RPRX) at 25.70% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Neurocrine Biosciences (NBIX) at 31.98% and Royalty Pharma (RPRX) at 81.32% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Neurocrine Biosciences (NBIX) at 21.45% and Royalty Pharma (RPRX) at 5.06% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Neurocrine Biosciences (NBIX) at 41.95% and Royalty Pharma (RPRX) at 23.09% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both Neurocrine Biosciences (NBIX) at 2.04 and Royalty Pharma (RPRX) at 1.29 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Neurocrine Biosciences (NBIX) at 0.12 carries an industry-typical debt-to-equity mix, while Royalty Pharma (RPRX) at 0.88 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neurocrine Biosciences (NBIX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a yield of 1.37%, ranking against industry peers normally.

Neurocrine Biosciences (NBIX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a payout of 60.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

Neurocrine Biosciences (NBIX) at 24.43 is near its industry’s usual P/E ratio, while Royalty Pharma (RPRX) at 43.99 sits in the richer quartile — RPRX needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Neurocrine Biosciences (NBIX) at 4.50 and Royalty Pharma (RPRX) at 14.79 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Neurocrine Biosciences (NBIX) at 4.30 and Royalty Pharma (RPRX) at 4.39 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics